Organization | GCS Ramsay Santé pour l’Enseignement et la Recherche

GCS Ramsay Santé pour l’Enseignement et la Recherche Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial

2020

NCT04394481

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

GCS Ramsay Santé pour l'Enseignement et la Recherche | GCS Ramsay Santé pour l’Enseignement et la Recherche | Scientific Committee

Active Ingredients

Drugs in Phase 4 Trials (5)

bupivacaine (Exparel) (1 trial)

dexamethasone (1 trial)

morphine (2 trials)

ropivacaine (naropin) (1 trial)

sufentanil (1 trial)

Drugs in Phase 3 Trials (1)

onabotulinumtoxinA (Botox) (1 trial)

Drugs in Phase 2 Trials (2)

C1 Esterase Inhibitor (Human) (Cinryze) (1 trial)

icatibant (firazyr) (1 trial)

Drugs in Other Trials (4)

chondroitin (1 trial)

epinephrine (levophed) (1 trial)

hyaluronic acid (1 trial)

lidocaine (xylocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Agnosia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 12